MedTrace Logo

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

NCT04924101 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2025-07-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage small cell Lung Cancer (ES-SCLC). No formal hypothesis testing will be performed for this study.

Conditions

Interventions

BIOLOGICAL

Pembrolizumab

IV infusion

BIOLOGICAL

MK-4830

IV infusion

BIOLOGICAL

Boserolimab

IV infusion

DRUG

Lenvatinib

Oral capsule

DRUG

Etoposide

IV infusion

DRUG

Cisplatin

IV infusion

DRUG

Carboplatin

IV infusion

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-15
Primary Completion
2025-06-23
Completion
2025-06-23
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Canada
  • Hungary
  • Israel
  • Italy
  • Poland
  • Russia
  • South Korea
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04924101 on ClinicalTrials.gov